Author: admin
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, July 05, 2024 (GLOBE NEWSWIRE) —
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 06/30/2024 | 100,093,635 | 88,029,364 |
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
Đề xuất
MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions
AIM ImmunoTech Announces Closing of its Rights Offering
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Curaechoice and Health Benefit Alliance Partner to Deliver No-Cost Healthcare to 161,000 Members Across 42 States
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autoliv announces appointment of new CFO